Unprecedented clinical trials completed in the United States have demonstrated that the new CRISPR-Cas12x system makes it possible to fully restore pancreatic cells in patients.
Thanks to this innovative method, 30 patients have already completely stopped daily insulin injections, marking a true breakthrough achievement in the history of medicine.
These gene editing results could radically alter approaches to treating Type 1 diabetes, as therapy to date has primarily focused on managing symptoms rather than eliminating the root cause of the disease.
Nevertheless, evaluating long-term safety and efficacy remains paramount for such trials, as large-scale application requires ensuring that the restored cells maintain their function over the years.
